Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Patients With Relapsed and/or Refractory Multiple Myeloma: Results From at Least 1-Year Follow-Up in all Patients

被引：0

作者：

Frigault, Matthew ^{[1
]}

Rosenblatt, Jacalyn ^{[2
]}

Dhakal, Binod ^{[3
]}

Raje, Noopur ^{[4
]}

Cook, Daniella ^{[1
]}

Gaballa, Mahmoud ^{[5
]}

Emmanuel-Alejandro, Estelle ^{[2
]}

Nissen, Danielle ^{[3
]}

Banerjee, Kamalika ^{[6
]}

Rotte, Anand ^{[6
]}

Heery, Christopher ^{[6
]}

Avigan, David ^{[2
]}

Jakubowiak, Andrzej ^{[7
]}

Bishop, Michael ^{[7
]}

机构：

[1] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA

[2] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA

[3] Med Coll Wisconsin, Milwaukee, WI 53226 USA

[4] Massachusetts Gen Hosp, Boston, MA 02114 USA

[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[6] Arcellx Inc, Redwood City, CA USA

[7] Univ Chicago, Chicago, IL 60637 USA

来源：

关键词：

MM; multiple myeloma; BCMA; plasma cell; anitocabtagene autoleucel;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MM-364

引用

页码：S553 / S553

页数：1